CTC
XTLB

Central Trust Company’s XTL Biopharmaceuticals XTLB Stock Holding History

Central Trust Company’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50
Closed -$203 – 1426
2023
Q4 		$203 Buy
+50
New +$190 ﹤0.01% 1369

Other funds holding XTLB

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Central Trust Company's XTLB Position: Q1 2024 in Review

Central Trust Company sold out of XTL Biopharmaceuticals (XTLB) in Q1 2024, closing a stake of 50 shares — an estimated $203 sold.

Central Trust Company first reported a position in XTLB in Q4 2023 and held it in 1 quarter. The position peaked at $203 in Q4 2023. 5 funds tracked by Wall St. Rank hold XTLB as of Q1 2024.

  • Central Trust Company reported no remaining XTL Biopharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Central Trust Company sold 50 XTL Biopharmaceuticals shares in Q1 2024, an estimated $203.
  • Central Trust Company first reported a position in XTL Biopharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Central Trust Company's XTL Biopharmaceuticals position peaked at $203 in Q4 2023.
  • 5 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q1 2024.

Based on Central Trust Company's 13F filing for Q1 2024, filed 24 Apr 2024.